Bruce Minksy, MD's, Expert Perspective: Radiotherapy in 2015
2015 ASTRO Annual MeetingASTRO President Bruce Minsky, MD, of MD Anderson Cancer Center, talks about the goals and highlights of this year’s ASTRO Annual Meeting.
ASTRO President Bruce Minsky, MD, of MD Anderson Cancer Center, talks about the goals and highlights of this year’s ASTRO Annual Meeting.
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).
Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).
Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).
Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).
Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).